Skip to main content
. 2022 Jun 14;10(6):1410. doi: 10.3390/biomedicines10061410

Figure 3.

Figure 3

Schematic illustration of BiTE, BiKE, and TriKE structure and mechanism of action. Bispecific antibodies containing single-chain variable fragment (scFv) specific for CD3 on T cells (BiTE therapy) or CD16 on NK cells (BiKE therapy) and a specific tumor-associated antigen (TAA) are used to trigger T and NK cell activation and cytokine release. TriKE therapy similarly contains scFV specific for CD16a and TAA, but also a humanized anti-CD16 heavy chain camelid single-domain antibody (sdAb) that provides signals for NK priming, expansion, and survival. By inducing immunologic synapse formation and costimulatory signals, BiTE, BiKE, and Trike therapy can overcome immune exhaustion and improve anti-tumor activity in the setting of the AML TME. Image created with Biorender.com (accessed on 17 May 2022).